DAFNA Capital Management LLC holds a focused book of 83 stocks worth $439.6M as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Fulcrum Therapeutics Inc and trimmed Revolution Medicines Inc. Their largest long position is Revolution Medicines Inc at 13% of the equity book.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
81% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices (an exit at the prior quarter-end), no cost basis
Other tracked managers holding the same core names as DAFNA Capital Management LLC
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| Morgan Stanley | 79 / 80 | $4.6B |
| UBS Group AG | 78 / 80 | $2.7B |
| BlackRock, Inc. | 77 / 80 | $14.7B |
| BNP Paribas Financial Markets | 77 / 80 | $3.8B |
| JPMorgan Chase & Co | 77 / 80 | $3.1B |
| Wells Fargo & Company | 74 / 80 | $766.6M |
| Royal Bank Of Canada | 73 / 80 | $544.1M |
| Geode Capital Management, LLC | 72 / 80 | $4.8B |
Ranked by the share of each fund's own book sitting in the names it shares with DAFNA Capital Management LLC: only funds sharing at least a tenth of the book qualify. Index giants, bank custody books and market makers are excluded. They hold everything, so their overlap says nothing.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Revolution Medicines Inc COM | $56.5M | 580.7K | 12.8% | ▼−3.9% Reduced · −24K sh | |
| 2 | SPDR S&P Biotech ETF ETF | $40.7M | 318.5K | 9.3% | ▼−5.3% Reduced · −18K sh | |
| 3 | Stereotaxis Inc COM NEW | $25.2M | 13.68M | 5.7% | —Held | |
| 4 | Day One Biopharmaceuticals I COM | $21.0M | 978.5K | 4.8% | ▼−2.1% Reduced · −21K sh | |
| 5 | Atricure Inc COM | $17.0M | 597.4K | 3.9% | —Held | |
| 6 | Ideaya Biosciences Inc COM | $15.9M | 476.7K | 3.6% | ▼−5.9% Reduced · −30K sh | |
| 7 | Xenon Pharmaceuticals Inc COM | $14.6M | 250.8K | 3.3% | ▼−13% Reduced · −37K sh | |
| 8 | Cytokinetics Inc COM NEW | $14.3M | 217.5K | 3.3% | ▼−41% Reduced · −154K sh | |
| 9 | Compass Pathways PLC SPONSORED ADS | $13.4M | 2.42M | 3.0% | ▲+198% Added · +1.6M sh | |
| 10 | Nektar Therapeutics COM NEW | $11.9M | 165.2K | 2.7% | ▲+120% Added · +90K sh | |
| 11 | Ishares Nasdaq Biotech Indx ETF | $10.5M | 62.1K | 2.4% | ▼−8.8% Reduced · −6K sh | |
| 12 | Arcus Biosciences Inc COM | $9.6M | 443.8K | 2.2% | ▲+2.9% Added · +13K sh | |
| 13 | Neurocrine Biosciences Inc COM | $9.3M | 70.6K | 2.1% | —Held | |
| 14 | Larimar Therapeutics Inc COM | $9.1M | 2.03M | 2.1% | ▲+116% Added · +1.1M sh | |
| 15 | Bicara Therapeutics Inc COM | $8.4M | 421.7K | 1.9% | ▲+61% Added · +160K sh | |
| 16 | Axogen Inc COM | $8.3M | 250.0K | 1.9% | ▼−48% Reduced · −227K sh | |
| 17 | Biohaven Ltd COM | $7.2M | 845.7K | 1.6% | ▼−11% Reduced · −110K sh | |
| 18 | Tandem Diabetes Care Inc COM NEW | $6.8M | 355.2K | 1.5% | —Held | |
| 19 | Denali Therapeutics Inc COM | $6.1M | 318.5K | 1.4% | —Held | |
| 20 | Ascendis Pharma A/s NOTE 2.250% 4/0 | $5.9M | 4.00M | 1.3% | —Held | |
| 21 | Century Therapeutics Inc COM | $5.5M | 2.43M | 1.3% | ▼−13% Reduced · −359K sh | |
| 22 | Dexcom Inc COM | $5.4M | 86.3K | 1.2% | ▼−2.3% Reduced · −2K sh | |
| 23 | Kalvista Pharmaceuticals Inc COM | $5.4M | 267.4K | 1.2% | ▼−25% Reduced · −89K sh | |
| 24 | Ascendis Pharma A/s SPONSORED ADR | $5.3M | 23.2K | 1.2% | ▼−18% Reduced · −5K sh | |
| 25 | MBX Biosciences Inc COM | $5.2M | 175.5K | 1.2% | ▲+6.2% Added · +10K sh | |
| 26 | Inogen Inc COM | $5.2M | 845.2K | 1.2% | ▲+2.2% Added · +18K sh | |
| 27 | Syndax Pharmaceuticals Inc COM | $5.1M | 217.4K | 1.2% | ▼−22% Reduced · −61K sh | |
| 28 | Alkermes PLC SHS | $4.9M | 139.5K | 1.1% | ▲+7.1% Added · +9K sh | |
| 29 | Stoke Therapeutics Inc COM | $4.3M | 130.9K | 1.0% | ▲+20% Added · +22K sh | |
| 30 | Biocryst Pharmaceuticals Inc COM | $4.1M | 430.2K | 0.9% | ▲+2.9% Added · +12K sh | |
| 31 | Galapagos NV SPON ADR | $3.9M | 130.2K | 0.9% | —Held | |
| 32 | Immunovant Inc COM | $3.7M | 150.5K | 0.9% | —Held | |
| 33 | Edgewise Therapeutics Inc COM | $3.5M | 112.2K | 0.8% | ▼−30% Reduced · −48K sh | |
| 34 | Maplight Therapeutics Inc COM | $3.5M | 171.0K | 0.8% | ▲+19% Added · +27K sh | |
| 35 | Allogene Therapeutics Inc COM | $3.3M | 1.37M | 0.8% | ▼−0.7% Reduced · −10K sh | |
| 36 | Procept Biorobotics Corp COM | $3.0M | 120.0K | 0.7% | —Held | |
| 37 | Align Technology Inc COM | $2.6M | 15.0K | 0.6% | ▼−6.3% Reduced · −1K sh | |
| 38 | Proqr Therapeutics N V SHS EURO | $2.5M | 1.57M | 0.6% | —Held | |
| 39 | Cybin Inc COM NEW | $2.4M | 498.4K | 0.5% | ▲+9.5% Added · +43K sh | |
| 40 | Rapport Therapeutics Inc COM | $2.3M | 75.0K | 0.5% | —Held | |
| 41 | Insulet Corp COM | $2.3M | 10.9K | 0.5% | ▲+58% Added · +4K sh | |
| 42 | Structure Therapeutics Inc SPONSORED ADS | $2.2M | 46.5K | 0.5% | ▲+26% Added · +10K sh | |
| 43 | Immatics NV SHS | $2.2M | 225.9K | 0.5% | ▼−14% Reduced · −35K sh | |
| 44 | Celldex Therapeutics Inc COM NEW | $2.2M | 68.5K | 0.5% | —Held | |
| 45 | Lexeo Therapeutics Inc COM | $2.2M | 377.1K | 0.5% | ▲+11% Added · +36K sh | |
| 46 | Alector Inc COM | $2.0M | 908.4K | 0.4% | —Held | |
| 47 | Viking Therapeutics Inc COM | $1.9M | 59.5K | 0.4% | —Held | |
| 48 | Kura Oncology Inc COM | $1.9M | 235.9K | 0.4% | —Held | |
| 49 | Profound Medical Corp COM NEW | $1.7M | 263.0K | 0.4% | ▼−7.9% Reduced · −23K sh | |
| 50 | Fulcrum Therapeutics Inc COM | $1.6M | 205.0K | 0.4% | ▲New New position |
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1389933/holdings"
Use Arkolith to show DAFNA Capital Management LLC's latest holdings, largest changes, and filing provenance.
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.